Page last updated: 2024-12-10
4-chlorobenzoyl coenzyme a
Description
4-chlorobenzoyl coenzyme A: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-chlorobenzoyl-CoA : A chlorobenzoyl-CoA that results from the formal condensation of the thiol group of coenzyme A with the carboxy group of 4-chlorobenzoic acid [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 3082839 |
| CHEBI ID | 15498 |
| SCHEMBL ID | 2931857 |
| MeSH ID | M0224107 |
Synonyms (15)
| Synonym |
|---|
| 4-cba-coa |
| 4-chlorobenzoyl coa |
| CHEBI:15498 |
| coenzyme a, s-(4-chlorobenzoate) |
| 3'-phosphoadenosine 5'-{3-[(3r)-4-{[3-({2-[(4-chlorobenzoyl)sulfanyl]ethyl}amino)-3-oxopropyl]amino}-3-hydroxy-2,2-dimethyl-4-oxobutyl] dihydrogen diphosphate} |
| 4-chlorobenzoyl coenzyme a |
| 117380-98-0 |
| C06387 |
| 4-chlorobenzoyl-coa |
| s-[2-[3-[[(2r)-4-[[[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-4-hydroxy-3-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl]oxy-2-hydroxy-3,3-dimethylbutanoyl]amino]propanoylamino]ethyl] 4-chlorobenzenecarbothioate |
| SCHEMBL2931857 |
| 9-{5-o-[{[(4-{[3-({2-[(4-chlorobenzoyl)sulfanyl]ethyl}imino)-3-hydroxypropyl]imino}-3,4-dihydroxy-2,2-dimethylbutoxy)(hydroxy)phosphoryl]oxy}(hydroxy)phosphoryl]-3-o-phosphonopentofuranosyl}-9h-purin-6-amine |
| DTXSID00922410 |
| Q27089480 |
| 4-chlorobenzoyl coa; (acyl-coa); [m+h]+; |
Drug Classes (2)
| Class | Description |
|---|
| chlorobenzoyl-CoA | A member of the class of benzoyl-CoAs in which the acyl group specified is chlorobenzoyl. |
| monochlorobenzenes | Any member of the class of chlorobenzenes containing a mono- or poly-substituted benzene ring in which only one substituent is chlorine. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 1 (11.11) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.18
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.18 (24.57) | | Research Supply Index | 2.30 (2.92) | | Research Growth Index | 4.48 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |